Insulin Glargine

In adults with type 1 diabetes, once-daily biosimilar insulin glargine GP40061 demonstrated similar changes in HbA1c, fasting glucose, and seven-point glucose profiles compared with originator insulin glargine over 26 weeks. Safety outcomes, including hypoglycemia rates and immune response, were comparable between the two preparations, supporting the clinical similarity and tolerability of glargine formulations.

This review describes insulin glargine as a smooth-acting basal insulin associated with less nocturnal and symptomatic hypoglycemia than NPH insulin in diabetes trials. It also notes that injection-site pain is reported in some studies and usually does not lead to discontinuation.

In healthy human subjects, intravenous infusion of insulin glargine acutely enhanced endothelium-dependent vasodilation to a similar extent as regular human insulin, without adverse metabolic or hemodynamic effects. The study also found comparable suppression of free fatty acids and stimulation of whole-body glucose uptake between glargine and regular insulin at matched infusion rates.

This review summarizes pharmacology, dosing, adverse effects, and interactions of insulin glargine, concluding that it is a well-tolerated basal insulin with a delayed onset and prolonged flat time-action profile. It supports lower hypoglycemia risk compared with older basal insulin options, though the underlying evidence is largely from diabetic populations rather than healthy subjects.